CAR-T cell therapy
Eligibility records and prior treatments translated for review, a bilingual liaison across workup, cell collection, and treatment, extended-stay housing for the multi-week timeline, and close follow-up throughout.
Conditions & symptoms
Relapsed blood cancers and other cases we coordinate around
This coordination is for patients dealing with relapsed or refractory leukemia, lymphoma, or multiple myeloma. We arrange eligibility-records translation, a bilingual liaison across workup and treatment, extended-stay housing for the multi-week timeline, and close follow-up — while every treatment decision stays with your hematologist.
- Relapsed or refractory B-cell leukemia and lymphoma
- Diffuse large B-cell lymphoma that returned after therapy
- Multiple myeloma after several prior treatment lines
- Eligibility questions after a hematologist's assessment
- Families comparing commercial and clinical-trial pathways
This list describes who this coordination is arranged around — it is not a diagnosis. Whether any procedure suits your condition is decided with your treating physician; MedicCN coordinates the care around it.
US vs China · reported
Reported treatment costs
Side by side: what the procedure is reported to cost a self-pay patient in the United States versus China, and how long each system typically makes you wait. Every figure links its source.
| Metric | United States | China |
|---|---|---|
| Self-pay price | US$373,000–515,000 list price per infusion; non-drug care adds ≈US$30,000–56,000 HMP Institute, Feb 2026 ↗ | US$120,000–220,000 all-in (commercial route) Yicai, Dec 2025 ↗ |
| · Trial / compassionate-use route | No published figure — cost plan via consultation | ≈US$50,000–80,000 Straits Times (Bloomberg), Jun 2026 ↗ |
| Typical wait | Median 27 days vein-to-vein (commercial Yescarta, CIBMTR registry analysis) CIBMTR via Kite, Dec 2022 ↗ | Timing confirmed by the hospital after review |
Third-party reference figures, not personal quotes. US cash prices are not your out-of-pocket cost after insurance or a UK/European price benchmark. Add MedicCN’s fixed USD 200–500 service fee (including visa fees, airport and hotel transfers, and 24-hour mobile Wi-Fi), the 10–25% medical coordination and bilingual accompaniment fee, accommodation, meals, flights, insurance and possible return visits. Confirm the total in your written plan. The rate depends on treatment type and accompaniment level and is confirmed in writing.
Planning your visit to China
Before booking travel, confirm the hospital appointment, written cost scope and required documents. These guides explain the practical arrangements around your care.
Start with your visit and cost questions
Tell us what you need help arranging for CAR-T cell therapy. We reply within 24 hours, including weekends, with the information needed, fee structure and next step. The initial conversation is free, by email or WhatsApp.